Open AccessDonor-Derived Mesenchymal Stem Cells Combined With Low-Dose Tacrolimus Prevent Acute Rejection After Renal Transplantation
Author(s) -
Yanwen Peng,
Ming Ke,
Lu Xu,
Longshan Liu,
Xiaoyong Chen,
Wenjie Xia,
Xiaobo Li,
Zhen Chen,
Junjie Ma,
Dehuai Liao,
Guanghui Li,
Jiali Fang,
Guangdong Pan,
Andy Peng Xiang
Publication year - 2013
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3182754c53
Subject(s) - tacrolimus , medicine , calcineurin , transplantation , mesenchymal stem cell , immunosuppression , urology , kidney transplantation , population , kidney , renal function , surgery , gastroenterology , pathology , environmental health
The deleterious side effects of calcineurin inhibitors have impaired long-term survival after renal allograft. New immunotherapy regimens that minimize or even eliminate calcineurin inhibitors are required to improve transplantation outcome. Mesenchymal stem cells (MSCs) represent a unique cell population with immunosuppressive function and prolong allograft survival in experimental organ transplant models.